October 5, 2014
by PharmaReviews
0 comments
Given a choice, most patients would prefer to take a drug orally instead of getting an injection. Unfortunately, many drugs, especially those made from large proteins, cannot be given as a pill because they get broken down in the stomach … Continue reading
October 5, 2014
by PharmaReviews
0 comments
Nonsteroidal anti-inflammatory drugs (NSAIDs) – such as ibuprofen and aspirin – increase one’s risk of upper gastrointestinal bleeding. When taken in combination with other drugs, this risk is significantly higher, according to new research appearing in the October issue of … Continue reading
August 15, 2014
by PharmaReviews
0 comments
Public Awareness Session on August 9th will be followed by formal inauguration by Governor of Baluchistan QUETTA: The 5th National Preventive Cardiology conference will be held here from August 9th to 10th 2014. It is being organized under the auspicious … Continue reading
August 15, 2014
by PharmaReviews
0 comments
KARACHI: Effective affordable treatment for Hepatitis-C is now available and the availability of new oral therapy Sofosobuvir ensures cure with complete elimination of the virus. This was stated by Prof. Saeed Hamid while speaking on Treatment of chronic Hepatitis-C at … Continue reading
August 15, 2014
by PharmaReviews
0 comments
National Institute for Health and Care Excellence (NICE) have lowered the threshold for people being offered statins to a 10% risk of developing cardiovascular disease in the next decade from 20% amid controversy. It is said that new guidelines lowering … Continue reading
August 3, 2014
by PharmaReviews
0 comments
European regulators have agreed to undertake an accelerated assessment of Eisai’s lenvatinib as a treatment for progressive radioiodine-refractory, differentiated thyroid cancer. The drug, which carries Orphan Status in the EU, is to be filed “imminently” and could become the … Continue reading
June 28, 2014
by PharmaReviews
0 comments
AstraZeneca has suffered a setback with advisors to the US Food and Drug Administration recommending against accelerated approval of olaparib for ovarian cancer. The agency’s Oncologic Drugs Advisory Committee has voted 11 to 2 that current evidence does not support … Continue reading
June 28, 2014
by PharmaReviews
0 comments
Advisors to the European Medicines Agency have backed Roche’s blockbuster Avastin for the most difficult to treat form of ovarian cancer. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve the use … Continue reading
June 24, 2014
by PharmaReviews
0 comments
Bayer has linked up with Dimension Therapeutics to develop a gene therapy for haemophilia A in a deal that could be worth about $250 million to the US biotech. The German group has long been a major player in haemophilia … Continue reading
June 24, 2014
by PharmaReviews
0 comments
Roche has hooked up with healthcare venture capitalist group Versant and research group Inception Sciences to create a new biotechnology company focused on developing treatments for multiple sclerosis. Crowned Inception 5, the newcomer will dedicate itself to designing novel … Continue reading